Tirzepatide is a dual GIP and GLP-1 receptor agonist used to treat type 2 diabetes and obesity. It enhances insulin secretion, reduces appetite, and slows gastric emptying. By targeting two key hormone pathways, it improves blood sugar control and promotes significant weight loss. It is administered as a once-weekly injection, with brand names including Mounjaro (for diabetes) and Zepbound (for weight loss).
